BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $380,869 | +2.2% | 53,795 | +1.6% | 0.00% | 0.0% |
| Q2 2023 | $372,641 | -17.3% | 52,932 | -2.0% | 0.00% | -25.0% |
| Q1 2023 | $450,502 | -25.2% | 54,017 | +3.0% | 0.00% | -33.3% |
| Q4 2022 | $602,344 | -5.3% | 52,469 | +4.0% | 0.01% | -14.3% |
| Q3 2022 | $636,000 | +20.2% | 50,443 | +0.8% | 0.01% | +40.0% |
| Q2 2022 | $529,000 | -33.1% | 50,043 | +2.9% | 0.01% | -16.7% |
| Q1 2022 | $791,000 | +18.6% | 48,640 | +1.0% | 0.01% | +20.0% |
| Q4 2021 | $667,000 | -4.2% | 48,142 | -0.5% | 0.01% | -16.7% |
| Q3 2021 | $696,000 | -8.4% | 48,403 | +0.7% | 0.01% | 0.0% |
| Q2 2021 | $760,000 | +45.3% | 48,082 | -6.5% | 0.01% | +20.0% |
| Q1 2021 | $523,000 | +37.3% | 51,399 | +0.4% | 0.01% | +66.7% |
| Q4 2020 | $381,000 | +112.8% | 51,204 | -1.9% | 0.00% | +50.0% |
| Q3 2020 | $179,000 | +7.8% | 52,220 | +50.2% | 0.00% | 0.0% |
| Q2 2020 | $166,000 | +130.6% | 34,772 | -3.9% | 0.00% | +100.0% |
| Q1 2020 | $72,000 | – | 36,168 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |